Axel Sjöblad, Managing Director of BioGaia AB, summarizes the fourth quarter of 2017 and answers the following questions:
- Q4 was a record quarter with 23% sales growth. Can you comment on this development?
- For the second quarter in a row Adult Health showed a significant increase in sales growth. Do you see any effects of inventory buildup or will we see the same rate growth going forward?
- On an annual basis, sales increased by 15% while EBIT grew to 234 MSEK (199). What were you most satisfied with during the year? What are the priorities for 2018?
- Despite an increase in dividend BioGaia has a strong financial position. Regarding acquisitions, are you mostly looking for new strains or companies?